Neurizon Therapeutics this week disclosed new preclinical data for its lead ALS candidate, NUZ-001, that the company will present at the BIO International Convention 2026.

The company presented the findings at the International Mental Health Conference on the Gold Coast and described clinically significant reductions in depression and trauma symptoms alongside improvements in quality of life and daily functioning.

MTPConnect has adopted a new name as it enters its second decade, rebranding itself as AUScelerate. The organisation said the change aims to better reflect its mission to commercialise Australian life sciences.

UniQuest and the Ellison Medical Institute have signed an exclusive licence that could push a promising University of Queensland treatment for advanced prostate cancer into first-in-human trials as early as 2027.

Recce Pharmaceuticals has received approval from the Human Research Ethics Committee to advance its Australian study of RECCE 327 Topical Gel to a pivotal Phase 3 trial for diabetic foot infections, a move the company says accelerates its global registration strategy.

Invion has taken a step to strengthen its clinical leadership by appointing Dr Colin Hopper, a globally recognised authority in photodynamic therapy, as a clinical advisor.

Tetratherix has announced that its joint venture, Tutelix, has received approval from the Human Research Ethics Committee in Australia to start an international pivotal clinical trial for its hydrogel spacer.

AusBiotech has announced that Australia's Biggest Week in Biotech 2027 will be held in Brisbane from 23–27 August, marking a shift from its traditional October timing.

Atmo Biosciences has been named a winner in Fast Company’s 2026 World Changing Ideas Awards, an annual program that recognises innovations delivering measurable impact across industries.

Racura Oncology has secured $34.3 million following a series of fundraising initiatives supported by new and existing shareholders, giving the company a strong cash balance to fully fund its RC220 clinical programs in Acute Myeloid Leukaemia, EGFRm non-small cell lung cancer and anthracycline cardioprotection in solid tumour patients.

Dr Christian Toouli, CEO and Managing Director of FivepHusion, said, "The ethics approval of the Phase II DART protocol is an exciting milestone towards our goal of evaluating Deflexifol as a promising therapy for these patients."

Dr Chris Baldwin, CEO and Managing Director, said, “Receipt of ethics approval for our KappaMab Phase 2b clinical trial in combination with pomalidomide and dexamethasone is a significant milestone for HaemaLogiX."

Percheron Therapeutics has announced the successful completion of manufacturing for a new batch of HMBD-002 drug substance ahead of planned clinical trials.

Neurizon Therapeutics has executed a long-term supply agreement with Elanco Animal Health that gives the company access to scalable Good Manufacturing Practice supply of monepantel, the active pharmaceutical ingredient in its lead asset NUZ‑001.

Melbourne-based Dimerix has granted Everest Medicines exclusive rights to commercialise DMX 200 for all indications, including Focal Segmental Glomerulosclerosis, in China, South Korea, and parts of Southeast Asia.

Paradigm Biopharmaceuticals has announced the completion of enrolment in its pivotal Phase 3 trial of Zilosul injectable pentosan polysulfate sodium for knee osteoarthritis, a milestone that moves the company into the next phase of clinical and corporate catalysts.

Nyrada says its PROTECT MI Phase 2a study of Xolatryp remains on track for completion in calendar 2027 and is moving through the staged rollout typical of first-in-patient cardiovascular studies.